{"entity":{"id":"pvr","kind":"target","name":"CD155 (PVR)","aka":["CD155","poliovirus receptor","Necl-5","NECL5","PVS"],"tldr":"CD155 is the molecule on tumour cells that TIGIT and CD96 read; normal tissue barely shows it, many tumours show a lot. Every TIGIT antibody works by breaking the CD155 handshake.","summary":"PVR (chromosome 19q13.31) encodes CD155, which mediates NK-cell adhesion and triggers NK effector functions through two NK-cell receptors, CD96 and CD226, at the immunological synapse (UniProt P15151). It is barely or weakly expressed in various normal human tissues but frequently over-expressed in malignant tumours, promotes invasion and migration, is associated with poor prognosis, and as the ligand of the co-stimulatory receptor CD226 and the co-inhibitory receptors TIGIT and CD96 it plays a dual role in onco-immunity (Kučan Brlić et al. 2017, Cell Mol Immunol).","asOf":"2026-09-24","links":[{"label":"HGNC HGNC:9705","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9705"},{"label":"UniProt P15151","url":"https://www.uniprot.org/uniprotkb/P15151/entry"},{"label":"NCBI Gene 5817","url":"https://www.ncbi.nlm.nih.gov/gene/5817"},{"label":"Kučan Brlić et al. 2017, Cell Mol Immunol (Europe PMC)","url":"https://europepmc.org/article/MED/28730595"}],"tags":["checkpoint-map"],"related":["tigit","cd96","nectin2","tiragolumab"],"cancers":[],"sections":[],"technologies":["tigit-blockade"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":["cancer-immunity-cycle"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Prevalence not recorded: HGNC and UniProt carry no positivity rates."],"provenance":{"editedBy":"OnCo checkpoint map (HGNC REST, UniProt REST, ClinicalTrials.gov v2)","editedOn":"2026-09-24"},"symbol":"PVR","role":["immune-checkpoint"],"sources":[{"label":"HGNC HGNC:9705","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9705","note":"approved symbol, name, aliases and cross-references"},{"label":"UniProt P15151","url":"https://www.uniprot.org/uniprotkb/P15151/entry","note":"protein name, function and tissue specificity"}],"specificitySources":[],"hgnc":"HGNC:9705","ensembl":"ENSG00000073008","uniprot":"P15151","entrez":"5817","biology":"A nectin-like adhesion molecule and the poliovirus receptor; the shared ligand of the DNAM-1/TIGIT/CD96 axis.","whereFound":["Weak in normal tissue, frequently over-expressed in malignant tumours (Kučan Brlić et al. 2017)"],"targetClass":"checkpoint","prevalence":[]},"route":"/targets/pvr/","neighbours":{"target":[{"id":"nectin2","kind":"target","name":"CD112 (nectin-2)","route":"/targets/nectin2/"},{"id":"cd96","kind":"target","name":"CD96","route":"/targets/cd96/"},{"id":"tigit","kind":"target","name":"TIGIT","route":"/targets/tigit/"}],"drug":[{"id":"tiragolumab","kind":"drug","name":"Tiragolumab","route":"/drugs/tiragolumab/"}],"technology":[{"id":"tigit-blockade","kind":"technology","name":"TIGIT blockade","route":"/technologies/tigit-blockade/"}],"pathway":[{"id":"cancer-immunity-cycle","kind":"pathway","name":"The cancer-immunity cycle","route":"/pathways/cancer-immunity-cycle/"}],"term":[{"id":"checkpoint","kind":"term","name":"Checkpoint (two meanings)","route":"/terms/checkpoint/"}]}}